Bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone plus prednisone in the PEACE-1 phase 3 trial.

According to data from the phase 3 PEACE-1 trial, presented during the 2022 ASCO Genitourinary Cancers Symposium, of patients with de novo metastatic castration-sensitive prostate cancer, abiraterone plus prednisone combined with androgen deprivation therapy (ADT) and docetaxel is associated with a modest to no increase in bone loss across the first 2 years of therapy, compared with ADT and docetaxel alone. Researchers measured bone mineral density of the lumbar spine, femoral neck, and total hip using dual x-ray absorptiometry at baseline and months 6, 12, and 24.